- Home
- ERAS vs SOR Comparison
ERAS vs SOR Comparison
Compare ERAS & SOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- SOR
- Stock Information
- Founded
- ERAS 2018
- SOR 1968
- Country
- ERAS United States
- SOR United States
- Employees
- ERAS N/A
- SOR N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- SOR Investment Managers
- Sector
- ERAS Health Care
- SOR Finance
- Exchange
- ERAS Nasdaq
- SOR Nasdaq
- Market Cap
- ERAS 439.7M
- SOR 368.8M
- IPO Year
- ERAS 2021
- SOR N/A
- Fundamental
- Price
- ERAS $1.71
- SOR $45.08
- Analyst Decision
- ERAS Buy
- SOR
- Analyst Count
- ERAS 6
- SOR 0
- Target Price
- ERAS $3.83
- SOR N/A
- AVG Volume (30 Days)
- ERAS 964.1K
- SOR 16.2K
- Earning Date
- ERAS 11-11-2025
- SOR 01-01-0001
- Dividend Yield
- ERAS N/A
- SOR 7.24%
- EPS Growth
- ERAS N/A
- SOR N/A
- EPS
- ERAS N/A
- SOR 6.50
- Revenue
- ERAS N/A
- SOR N/A
- Revenue This Year
- ERAS N/A
- SOR N/A
- Revenue Next Year
- ERAS N/A
- SOR N/A
- P/E Ratio
- ERAS N/A
- SOR $6.41
- Revenue Growth
- ERAS N/A
- SOR N/A
- 52 Week Low
- ERAS $1.01
- SOR $36.41
- 52 Week High
- ERAS $3.31
- SOR $42.75
- Technical
- Relative Strength Index (RSI)
- ERAS 59.36
- SOR 52.19
- Support Level
- ERAS $1.53
- SOR N/A
- Resistance Level
- ERAS $1.69
- SOR $45.53
- Average True Range (ATR)
- ERAS 0.10
- SOR 0.49
- MACD
- ERAS 0.01
- SOR -1.61
- Stochastic Oscillator
- ERAS 96.20
- SOR 98.38
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.